THURSDAY, July 2, 2020 (HealthDay News) — An experimental COVID-19 vaccine yielded promising results in early testing, according to Pfizer and its German partner BioNTech.
Preliminary findings show that the 45 study volunteers who received either a low or medium dose, in two shots about a month apart, had immune responses in the range expected to protect against the disease, the Associated Press reported.
The results have been submitted for publication in a scientific journal but not yet reviewed.
Pfizer and BioNTech are working on four experimental vaccines. About 15 different COVID-19 vaccine candidates are in human testing worldwide, with several poised to begin large, last-stage studies to determine if they’re actually effective, the AP reported.
Copyright © 2019 HealthDay. All rights reserved.
SLIDESHOW
Whooping Cough (Pertussis) Symptoms, Vaccine Facts
See Slideshow
